908 Devices Inc. filings document an operating company that sells common stock under MASS on the Nasdaq Global Market and reports on handheld chemical analysis tools used in health, safety and defense technology markets. Form 8-K reports furnish operating and financial results, revenue outlook materials, material-event disclosures, material agreements, capital-structure matters and related exhibits.
Proxy materials cover annual meeting voting matters, including director elections, auditor ratification, executive compensation votes and the frequency of future advisory compensation votes. The filing record also includes governance disclosures tied to board composition, annual meeting procedures, shareholder voting mechanics and emerging growth company status.
908 Devices Inc. (MASS) reports that AWM Investment Company, Inc., a ten percent owner, indirectly sold 50,000 shares of common stock in open-market transactions on August 20–21, 2026. The sales, executed through limited partnerships advised by AWM, occurred at weighted average prices of about $10.52–$10.61 per share.
AWM is investment adviser to several Special Situations funds and has sole voting and investment power over large share blocks they hold. AWM disclaims beneficial ownership of these shares except to the extent of its pecuniary interest.
908 Devices Inc. insider Kevin J. Knopp, President and CEO, reported selling a total of 27,622 shares of common stock in August 2026 under a Rule 10b5-1 trading plan adopted on May 20, 2025. Sales included 7,622 shares on August 13 at a weighted average $10.06 per share (actual prices ranged from $10.05 to $10.12) and 20,000 shares on August 17 at a weighted average $10.35 per share (range $10.08 to $10.45). Separately, 541,223 shares are held indirectly by The Kevin J. Knopp Irrevocable Trust of 2018, for which the trustee, Knopp’s brother-in-law, has sole voting and dispositive control; Knopp may be deemed the beneficial owner.
Kevin Knopp has filed a Form 144 indicating an intent to sell up to 20,000 shares of MASS common stock through Merrill Lynch on NASDAQ. These shares are identified as Founder Shares acquired from the issuer for cash on 02/10/2012. The filing notes that MASS had 37,813,621 common shares outstanding as of 08/17/2026 and that Knopp has sold multiple small common stock blocks in the open market over the past three months.
908 Devices Inc. received an amended Schedule 13G reporting that ARCH Venture Fund VII, L.P. is the record owner of 5,725,045 shares of Common Stock as of June 30, 2026. Through their general-partner structure, ARCH Venture Partners VII, L.P. and ARCH Venture Partners VII, LLC may be deemed to beneficially own the same shares, with shared voting and dispositive power.
Based on 41,333,705 shares of Common Stock outstanding as of August 7, 2026, each of the ARCH entities reports beneficial ownership of 13.9% of the class. Managing director Keith Crandell reports beneficial ownership of 5,824,877 shares, or 14.1%, including options and restricted stock units, and has both sole and shared voting and dispositive power over different portions of these holdings. The filing notes that each reporting person disclaims beneficial ownership except for shares held of record.
908 Devices Inc. common stock is reported as being beneficially owned by ARK Investment Management LLC and its CEO/CIO, Catherine D. Wood. They report ownership of 2,027,920 shares of common stock, representing 5.32% of the outstanding class.
ARK has sole voting and dispositive power over the 2,027,920 shares, while Catherine D. Wood reports shared voting and dispositive power over the same shares and no sole authority. The filing notes that no ARK client exceeds a 5% interest in these securities other than ARK Genomic Revolution ETF.
908 Devices Inc. received an updated ownership report from AWM Investment Company, Inc., an investment adviser to several Special Situations funds. AWM reported beneficial ownership of 4,879,773 shares of 908 Devices common stock, representing 11.8% of the outstanding class as of this filing.
AWM has sole voting and dispositive power over these shares, which are held across multiple funds: 577,077 shares by Special Situations Cayman Fund, 2,020,434 by Special Situations Fund III QP, 266,802 by Special Situations Private Equity Fund, 338,137 by Special Situations Technology Fund, and 1,677,323 by Special Situations Technology Fund II. Control of AWM and the funds’ general partners is described as resting with principals David M. Greenhouse and Adam C. Stettner.
908 Devices Inc. director Christopher D. Brown reported two open-market sales of common stock. On August 10, 2026, he sold 9,442 shares at a weighted average price of $9.03 per share, in multiple trades between $9.00 and $9.08. On August 11, 2026, he sold 8,358 shares at a weighted average price of $9.23, in trades between $9.06 and $9.36. The transactions, totaling 17,800 shares, were made pursuant to a Rule 10b5-1 trading plan adopted on November 24, 2025.
908 Devices Inc. President and CEO Kevin J. Knopp reported open-market sales of an aggregate 149,013 shares of common stock over August 10–12, 2026, at weighted average prices around $9.06–$10.16, in transactions made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2025. An additional 541,223 shares are reported as indirectly owned through The Kevin J. Knopp Irrevocable Trust of 2018, for which his brother-in-law, as trustee, has sole voting and dispositive control, while Knopp may be deemed the beneficial owner.
A shareholder of MASS filed a notice to sell 140,000 shares of common stock through Merrill Lynch, with an indicated aggregate market value of $1,347,000. The filing lists 37,813,621 common shares outstanding and contemplates sales beginning on August 11, 2026 on NASDAQ.
The form identifies the securities as Founder Shares originally acquired from the issuer for cash on February 10, 2012. It also discloses prior open-market sales by Kevin Knopp over the past three months, including multiple transactions between June 23 and August 10, 2026.
908 Devices Inc. develops handheld and program devices for chemical analysis serving defense, public safety and industrial customers. For the six months ended June 30, 2026, revenue from continuing operations was $29.5 million, up from $24.8 million, driven mainly by handheld product sales. Q2 revenue was $16.1 million.
The company reported a continuing-operations net loss of $23.8 million for the first half of 2026 and an accumulated deficit of $247.2 million. Results were pressured by operating expenses of $40.9 million, including a $12.8 million non-cash increase in contingent consideration tied to recent acquisitions.
Liquidity remains solid with $63.0 million of cash and $38.5 million of marketable securities and positive operating cash flow of $4.4 million in the first half. The company closed the NIRLAB acquisition, expanding narcotics-detection capabilities, and continues to recognize the effects of its 2025 Desktop Portfolio divestiture and related transition services. A new $20 million undrawn revolving credit facility extends financial flexibility.